Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating ...
Glox Therapeutics Strengthens Team Appointing Dr Michael Murray as Chair and Dr Nel Moore as Scientific Advisory Board Member
Glox Therapeutics appoints Dr Michael Murray as Chair and Dr Nel Moore as SAB Member to support development of precision ...
Coveo Solutions Inc.: Coveo Reports Third Quarter Fiscal 2025 Financial Results
SaaS Subscription Revenue(1) of $32.3 million, at the top end of previous guidanceRecord new bookings in the quarter, with accelerating contribution from CommerceContinued ...